Published in Cancer Biol Ther on April 27, 2010
Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 28.05
EGFR antagonists in cancer treatment. N Engl J Med (2008) 9.68
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol (1999) 2.75
Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol (2002) 1.83
Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials. Breast Cancer Res Treat (2010) 1.79
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist (2009) 1.53
Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer (2010) 1.52
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast. Cancer (1997) 1.40
Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol (2008) 1.39
Panitumumab. Nat Rev Drug Discov (2006) 1.31
Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer (2005) 1.19
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther (2010) 1.10
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer. J Oncol (2009) 1.02
Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. Int J Cancer (2007) 0.97
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. Semin Oncol (2002) 0.96
Role of vascular endothelial growth factor during breast cancer. Bull Exp Biol Med (2002) 0.87
Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions. Cancer Res (2005) 2.09
A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm. Nature (2002) 1.89
P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-alpha and promotes hyperplasia in mammary epithelium. EMBO J (2002) 1.75
p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem (2003) 1.70
Retracted Metastasis-associated protein 1 deregulation causes inappropriate mammary gland development and tumorigenesis. Development (2004) 1.67
Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells. Cancer Res (2006) 1.67
Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells. Cancer Res (2004) 1.59
Estrogen attenuates ischemic oxidative damage via an estrogen receptor alpha-mediated inhibition of NADPH oxidase activation. J Neurosci (2009) 1.54
Functional inactivation of a transcriptional corepressor by a signaling kinase. Nat Struct Biol (2003) 1.50
Rapid estrogen signaling in the brain. Neurosignals (2008) 1.43
PELP1 is a reader of histone H3 methylation that facilitates oestrogen receptor-alpha target gene activation by regulating lysine demethylase 1 specificity. EMBO Rep (2010) 1.39
Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations. Clin Cancer Res (2006) 1.38
Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein. J Biol Chem (2003) 1.31
Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One (2012) 1.31
C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc Natl Acad Sci U S A (2011) 1.31
p21-activated kinase 1 interacts with and phosphorylates histone H3 in breast cancer cells. EMBO Rep (2002) 1.30
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res (2007) 1.28
Emerging functions of p21-activated kinases in human cancer cells. J Cell Physiol (2002) 1.25
Extranuclear functions of ER impact invasive migration and metastasis by breast cancer cells. Cancer Res (2010) 1.20
MICoA, a novel metastasis-associated protein 1 (MTA1) interacting protein coactivator, regulates estrogen receptor-alpha transactivation functions. J Biol Chem (2003) 1.15
The cell fate determination factor DACH1 is expressed in estrogen receptor-alpha-positive breast cancer and represses estrogen receptor-alpha signaling. Cancer Res (2009) 1.14
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res (2011) 1.14
Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res (2005) 1.13
Upstream determinants of estrogen receptor-alpha regulation of metastatic tumor antigen 3 pathway. J Biol Chem (2004) 1.12
B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. J Immunol (2010) 1.10
Significance of ER-Src axis in hormonal therapy resistance. Breast Cancer Res Treat (2010) 1.10
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res (2012) 1.08
Cyclin-dependent kinase-mediated phosphorylation plays a critical role in the oncogenic functions of PELP1. Cancer Res (2010) 1.08
Therapeutic significance of estrogen receptor β agonists in gliomas. Mol Cancer Ther (2012) 1.07
Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway. Mol Cancer Res (2008) 1.07
Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer (2011) 1.06
Proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2. Mol Endocrinol (2006) 1.06
Role of PELP1/MNAR signaling in ovarian tumorigenesis. Cancer Res (2008) 1.05
Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res (2011) 1.02
Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1: potential estrogen receptor autocrine signaling loop in breast cancer cells. Mol Endocrinol (2007) 1.01
Epigenetics of estrogen receptor signaling: role in hormonal cancer progression and therapy. Cancers (Basel) (2011) 1.00
Cloning and functional characterization of PELP1/MNAR promoter. Gene (2004) 0.99
Regulation of phosphoglucomutase 1 phosphorylation and activity by a signaling kinase. Oncogene (2004) 0.98
PELP1: A novel therapeutic target for hormonal cancers. IUBMB Life (2010) 0.98
Metastasis-associated protein 1 interacts with NRIF3, an estrogen-inducible nuclear receptor coregulator. Mol Cell Biol (2004) 0.98
Five friends of methylated chromatin target of protein-arginine-methyltransferase[prmt]-1 (chtop), a complex linking arginine methylation to desumoylation. Mol Cell Proteomics (2012) 0.97
Essential functions of p21-activated kinase 1 in morphogenesis and differentiation of mammary glands. J Cell Biol (2003) 0.97
Extranuclear coactivator signaling confers insensitivity to tamoxifen. Clin Cancer Res (2009) 0.97
Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Cancer Res (2007) 0.95
PELP1--a novel estrogen receptor-interacting protein. Mol Cell Endocrinol (2008) 0.95
Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) interacts with PELP1 and activates MAPK. J Biol Chem (2005) 0.94
The clinical relevance of steroid hormone receptor corepressors. Clin Cancer Res (2005) 0.93
Cloning, expression, and localization of MNAR/PELP1 in rodent brain: colocalization in estrogen receptor-alpha- but not in gonadotropin-releasing hormone-positive neurons. Endocrinology (2005) 0.93
Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res (2011) 0.89
Regulation of rDNA transcription by proto-oncogene PELP1. PLoS One (2011) 0.88
9-cis-retinoic acid up-regulates expression of transcriptional coregulator PELP1, a novel coactivator of the retinoid X receptor alpha pathway. J Biol Chem (2006) 0.88
Altered localization of a coactivator sensitizes breast cancer cells to tumor necrosis factor-induced apoptosis. Mol Cancer Ther (2006) 0.87
Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis (2006) 0.87
Activating transcription factor 4 overexpression inhibits proliferation and differentiation of mammary epithelium resulting in impaired lactation and accelerated involution. J Biol Chem (2003) 0.86
Dynein light chain 1 phosphorylation controls macropinocytosis. J Biol Chem (2004) 0.85
KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget (2013) 0.84
Hypersensitivity of the hippocampal CA3 region to stress-induced neurodegeneration and amyloidogenesis in a rat model of surgical menopause. Brain (2013) 0.83
Estrogen induces expression of BCAS3, a novel estrogen receptor-alpha coactivator, through proline-, glutamic acid-, and leucine-rich protein-1 (PELP1). Mol Endocrinol (2007) 0.83
Estrogen receptor-β activation in combination with letrozole blocks the growth of breast cancer tumors resistant to letrozole therapy. Steroids (2011) 0.82
Estrogen receptor-beta mediates the protective effects of aromatase induction in the MMTV-Her-2/neu x aromatase double transgenic mice. Horm Cancer (2012) 0.82
Novel role of PELP1 in regulating chemotherapy response in mutant p53-expressing triple negative breast cancer cells. Breast Cancer Res Treat (2015) 0.80
Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells. Mol Pharm (2014) 0.80
Regulation of hormonal therapy resistance by cell cycle machinery. Gene Ther Mol Biol (2008) 0.79
Integrin-linked kinase 1: role in hormonal cancer progression. Front Biosci (Schol Ed) (2011) 0.78